Gina Z. D'Amato, MD.

@GinaDAmatoMD1

Associate Professor of Medicine Sarcoma Medical Oncology Assistant Director of Clinical Research Sylvester Comprehensive Cancer Center

Vrijeme pridruživanja: studeni 2015.

Tweetovi

Blokirali ste korisnika/cu @GinaDAmatoMD1

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @GinaDAmatoMD1

  1. 31. sij

    I have 30 days to raise as much $$ as possible for cancer research. please donate!!

    Poništi
  2. 24. sij

    Yay!! Another promising drug FDA for sarcoma!!! Tazemetostat for epithelioid sarcoma! Congrats to for all the work he did to help get the approval!!

    Poništi
  3. ⁩ ⁦⁩ ⁦⁩ ⁦ alliance ⁦⁩ FINALLY a tool that Gynecologists can use to predict possible uterine leiomyosarcoma and prevent harmful surgeries!! Spread the word!!!

    Poništi
  4. Prikaži ovu nit
    Poništi
  5. So proud to be working again at a NCI designated cancer center! Can you see the #1 sarcoma expert is standing as the leading researchers who made it happen?

    Prikaži ovu nit
    Poništi
  6. Poništi
  7. proslijedio/la je Tweet
    3. lip 2019.

    There are several active regimens for patients with relapsed/refractory after VIDE or (VDC/IE) high-dose ifosfamide 14gm/m2 bolus

    Poništi
  8. proslijedio/la je Tweet
    3. lip 2019.

    Cabozantinib is safe and has promising activity for patients with . 12 week progression free rate 58%. ORR 18%.

    Poništi
  9. proslijedio/la je Tweet
    2. lip 2019.

    congratulations to Dr. Tap and Verweij for an excellent and thoughtful presentation and discussion. Agree, we should collaborate globally and across the age range of sarcoma patients for subtype sarcoma clinical trials and data sharing.

    Poništi
  10. proslijedio/la je Tweet
    3. lip 2019.

    Preop radiotherapy is safe and effective in pts with retroperitoneal liposarcoma

    Poništi
  11. proslijedio/la je Tweet
    3. lip 2019.

    Nab-sirolimus is safe and active in patients with metastatic malignant PEComa. ORR 42%, mPFS 8.4 months. Mutant TSC1>TSC2 and activated S6 predict clinical benefit.

    Poništi
  12. Poništi
  13. 100% of the funds raised goes directly to cancer research at Sylvester Cancer Center!!

    Prikaži ovu nit
    Poništi
  14. I am fundraising for DCC IX. Help me reach my fundraising goal! via

    Prikaži ovu nit
    Poništi
  15. So excited to come back home to join an amazing sarcoma center with the best boss ever!!

    Poništi
  16. proslijedio/la je Tweet
    1. lip 2018.

    Great seeing you , medical oncologist extraordinaire! Learning a lot at already.

    Poništi
  17. We need better cancer treatments! Please help by donating to leukemia lymphoma society!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·